Position of the Transparency Council – Yervoy (ipilimumab)

At its meeting on 18 July 2022 the Transparency Council adopted Position No. 66/2022  on the evaluation of the drug Yervoy (ipilimumab) as part of the drug programme: “Treatment of non-small or small cell lung cancer (ICD-10 C 34) and treatment of pleural mesothelioma (ICD-10 C45)”.

Publication in Public Information Bulletin (BIP)